At Day 2, Anakinra treatment also led to a significant reduction of BAL protein levels (Figure 1B) as well as MIP‐2 concentration (Figure 1C), which are two classical ALI markers. This evidence concerns the gene CXCL2 and acute respiratory distress syndrome.